JP2017524719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524719A5 JP2017524719A5 JP2017507823A JP2017507823A JP2017524719A5 JP 2017524719 A5 JP2017524719 A5 JP 2017524719A5 JP 2017507823 A JP2017507823 A JP 2017507823A JP 2017507823 A JP2017507823 A JP 2017507823A JP 2017524719 A5 JP2017524719 A5 JP 2017524719A5
- Authority
- JP
- Japan
- Prior art keywords
- esketamine
- patient
- depression
- pharmaceutical composition
- dosing regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims description 19
- 229960000450 esketamine Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 11
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 6
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 5
- 238000003205 genotyping method Methods 0.000 claims description 5
- 229960003299 ketamine Drugs 0.000 claims description 5
- 108700028369 Alleles Proteins 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036896P | 2014-08-13 | 2014-08-13 | |
| US62/036,896 | 2014-08-13 | ||
| PCT/US2015/044830 WO2016025581A1 (en) | 2014-08-13 | 2015-08-12 | Method for the treatment of depression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524719A JP2017524719A (ja) | 2017-08-31 |
| JP2017524719A5 true JP2017524719A5 (OSRAM) | 2018-09-20 |
| JP6545788B2 JP6545788B2 (ja) | 2019-07-17 |
Family
ID=55301311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507823A Active JP6545788B2 (ja) | 2014-08-13 | 2015-08-12 | うつ病の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10098854B2 (OSRAM) |
| EP (1) | EP3179993B1 (OSRAM) |
| JP (1) | JP6545788B2 (OSRAM) |
| KR (1) | KR20170040800A (OSRAM) |
| CN (1) | CN106714789A (OSRAM) |
| AU (2) | AU2015301782B2 (OSRAM) |
| CA (1) | CA2957926A1 (OSRAM) |
| IL (2) | IL250490A0 (OSRAM) |
| MA (1) | MA40462A (OSRAM) |
| MX (1) | MX2017001908A (OSRAM) |
| WO (1) | WO2016025581A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2755809T3 (es) | 2013-03-15 | 2020-04-23 | Janssen Pharmaceutica Nv | Composición farmacéutica de hidrocloruro de S-ketamina |
| RS62516B1 (sr) | 2013-09-13 | 2021-11-30 | Univ Chiba Nat Univ Corp | Primena r-ketamina i njegove soli kao farmaceutskih proizvoda |
| WO2015108985A1 (en) * | 2014-01-14 | 2015-07-23 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| WO2016044150A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| JP6845162B2 (ja) | 2015-06-27 | 2021-03-17 | シェノックス・ファーマシューティカルズ・エルエルシー | ケタミン経皮送達システム |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| BR112020012473A2 (pt) * | 2017-12-22 | 2020-11-24 | Janssen Pharmaceuticals, Inc. | escetamina para o tratamento da depressão |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| EP3753557B1 (en) | 2018-02-15 | 2025-11-05 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| CA3099293A1 (en) | 2018-05-04 | 2019-11-07 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| PL3628313T3 (pl) * | 2018-09-28 | 2025-06-23 | Novohale Therapeutics, Llc | Kompozycja ketaminy do zastosowania w sposobie leczenia depresji przez podawanie dopłucne |
| CN113597645B (zh) | 2019-01-23 | 2025-12-09 | 密歇根大学董事会 | 用于重建药物应答和疾病网络的方法和系统以及其用途 |
| CN114126595A (zh) | 2019-03-05 | 2022-03-01 | 杨森制药公司 | 用于治疗抑郁症的艾司氯胺酮 |
| WO2021262871A1 (en) * | 2020-06-25 | 2021-12-30 | Greenway Dna Inc. | Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| PT1113785E (pt) | 1998-07-24 | 2005-08-31 | Seo Hong Yoo | Solucoes aquosas limpidas de acidos biliares |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| MXPA05000294A (es) | 2002-07-30 | 2005-08-19 | Peter Migaly | Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas. |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| CN101466364A (zh) * | 2006-03-22 | 2009-06-24 | 纽约大学西奈山医学院 | 鼻内施用氯胺酮治疗抑郁症 |
| EP2029136A4 (en) | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | TREATMENT FOR DEPRESSION DISEASES |
| DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| WO2009131794A1 (en) | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US8846765B2 (en) | 2010-06-15 | 2014-09-30 | Gruenenthal Gmbh | Pharmaceutical combination |
| EP2780467B1 (en) * | 2011-11-14 | 2018-10-17 | Alfasigma S.p.A. | Assays and methods for selecting a treatment regimen for a subject with depression and methods for treatment |
| CN104519878A (zh) | 2012-03-12 | 2015-04-15 | 詹森药业有限公司 | 用于治疗顽固性或难治性抑郁症的艾氯胺酮 |
| KR20150096370A (ko) | 2012-08-23 | 2015-08-24 | 스튜어트 엘. 웨그 | 항불안제 조성물, 제형 및 사용방법 |
| KR20150142012A (ko) | 2013-04-12 | 2015-12-21 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 외상후 스트레스 장애의 치료 방법 |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
-
2015
- 2015-08-12 JP JP2017507823A patent/JP6545788B2/ja active Active
- 2015-08-12 CN CN201580043454.XA patent/CN106714789A/zh active Pending
- 2015-08-12 EP EP15831762.8A patent/EP3179993B1/en active Active
- 2015-08-12 MA MA040462A patent/MA40462A/fr unknown
- 2015-08-12 AU AU2015301782A patent/AU2015301782B2/en not_active Ceased
- 2015-08-12 MX MX2017001908A patent/MX2017001908A/es unknown
- 2015-08-12 CA CA2957926A patent/CA2957926A1/en not_active Abandoned
- 2015-08-12 US US14/824,513 patent/US10098854B2/en active Active
- 2015-08-12 WO PCT/US2015/044830 patent/WO2016025581A1/en not_active Ceased
- 2015-08-12 KR KR1020177006277A patent/KR20170040800A/ko not_active Ceased
-
2017
- 2017-02-07 IL IL250490A patent/IL250490A0/en active IP Right Grant
-
2020
- 2020-12-03 AU AU2020281101A patent/AU2020281101A1/en not_active Abandoned
- 2020-12-21 IL IL279627A patent/IL279627A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524719A5 (OSRAM) | ||
| JP2017528483A5 (OSRAM) | ||
| Montgomery et al. | A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine | |
| Farlow et al. | Pharmacologic treatment of cognition in Alzheimer's dementia | |
| Malhi et al. | Pharmacological management of unipolar depression | |
| JP2024133462A (ja) | 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム | |
| CA2923685A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| MX2017001908A (es) | Metodo para el tratamiento de la depresion. | |
| JP2019514858A5 (OSRAM) | ||
| JP2015504871A5 (OSRAM) | ||
| JP2014502641A5 (OSRAM) | ||
| JP2025137763A (ja) | 絶食条件下でのタシメルテオンの投与 | |
| JP2015505564A5 (OSRAM) | ||
| JP2016506933A5 (OSRAM) | ||
| JP2017533220A5 (OSRAM) | ||
| JP2017514853A5 (OSRAM) | ||
| JP2016515586A5 (OSRAM) | ||
| JP2016512817A5 (OSRAM) | ||
| Kim et al. | Association of 5-HT3B receptor gene polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting | |
| JP2016510343A5 (OSRAM) | ||
| Elazar et al. | Emerging concepts for the treatment of hepatitis delta | |
| JP2020516663A5 (OSRAM) | ||
| Lima et al. | The effect of an inhibitor of gut serotonin (LP533401) during the induction of periodontal disease | |
| JP2019504860A5 (OSRAM) | ||
| NZ621356A (en) | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |